ArticleDrug and alcohol dependence2025
Clinical pharmacist practitioners prescribing of buprenorphine for opioid use disorder.
Article in Drug and alcohol dependence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Impact of an Interdisciplinary Educational Intervention on Healthcare Provider Knowledge and Beliefs Regarding Opioid Harm Reduction in Older Adults: A Pre-Post Survey Study.Pharmacy (Basel, Switzerland) · 2026Article
- Differences in buprenorphine initiation and retention for opioid use disorder between primary care and substance use disorder specialty care settings.Journal of substance use and addiction treatment · 2026Article
- A short communication of pain outcomes following a pharmacist-delivered alcohol and opioid use reduction intervention.Drug and alcohol dependence reports · 2026Article
- The Roles, Activities, and Opportunities of Clinical Pharmacists in a National Initiative to Improve Office-Based Buprenorphine Care.Substance use : research and treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundClinical Pharmacist Practitioners (CPPs) have a long history of collaborating with other prescribers for the provision of buprenorphine medication treatment for opioid use disorder (B-MOUD). In January 2023, with the removal of the DATA 2000 X-waiver process, CPPs were allowed to prescribe B-MOUD in states that allow CPP prescriptive authority of controlled substances. We sought to examine CPP prescribing patterns of B-MOUD in a large heath care system in 2023.
methodsWe conducted a retrospective cohort study of patients with opioid use disorder (OUD) who received B-MOUD care in 2023 within the Veterans Health Administration (VHA). B-MOUD was defined as a formulation of buprenorphine indicated for OUD. We characterized Veterans who were prescribed B-MOUD by CPPs and examined the characteristics of these prescriptions and the episodes of care (EOC).
resultsIn 2023, 22,863 Veterans received B-MOUD; 1090 (4.8 %) from a CPP. Veterans prescribed B-MOUD by CPPs were primarily 36-50 years old (n = 419, 38.4 %), male (n = 987, 90.6 %), white (n = 987, 90.6 %), non-Hispanic/Latino (n = 1043, 95.7 %), and in urban areas (n = 648, 59.4 %). 110 CPPs prescribed B-MOUD in 36 states representing 1.9 % of all B-MOUD prescribers in 2023. CPPs prescribed 5258 B-MOUD prescriptions, conducted 339 (2.7 %) initiations, were involved in 1162 (4.2 %) of all EOC throughout the year, and were the sole prescriber for 16.6 % of EOC. CPP-involved EOC had 86.9 % (n = 867) 90-day retention.
conclusionWhen they were able to, VHA CPPs were early adopters in prescribing B-MOUD. B-MOUD prescribing by CPPs is an emerging opportunity to further expand access to B-MOUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.